Endocrine therapies such as tamoxifen are classical treatments for ERα-positive breast cancer, especially for Luminal A subtype [32], therefore, we verified whether ATP6AP1 would have an effect on the drug sensitivity of TAM-treated luminal breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.